EXCIPIENT DRUG MASTER FILE
This article was originally published in The Gold Sheet
Executive Summary
...reform efforts may open the door to new pharmaceutical inactive ingredients. In discussions between FDA and industry on the DMF process, the concept of a third-party review of new excipients has been gaining momentum. International harmonization and electronic formatting are also being targeted to improve the DMF component of the drug approval process. Monograph harmonization continues as USP seeks to shore up its part of the excipient regulatory framework. Industry is developing guidances specific to excipient and packaging master files to help fill a gap in agency instructions.
You may also be interested in...
McKinsey Survey Highlights Progress, Challenges in Adoption of QbD
Drug manufacturers are adopting QbD but there are exceptions, especially among some generics firms, McKinsey finds in industry survey. The top challenge to further adoption: misalignment between R&D and commercial operations. Second is a lack of belief in the business case. However, the cost turns out to be low and the financial reward high, McKinsey says.
Manufacturers Encouraged to Enhance Clinical Relevance of Quality With QbD
Using QbD to set specs that make a difference to patients is hard but important work, FDA's Woodcock says. Prasugrel, levothyroxine, pallodone examples explored. How to establish a 'work space.' How to make the right correlations.
Biotech QbD Encounters Uncertainties Over Definitions and Regulatory Relief
As biotech firms begin to pilot QbD they wrestle with FDA over non-critical process parameters, postapproval changes and more. They are exploring how to define design spaces, change them, identify their edges. And they're still wondering what regulatory relief they might get in return for investing in quality-by-design studies.